Join Growin Stock Community!

SanofiSNY.US Overview

US StockHealthcare
(No presentation for SNY)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

SNY AI Insights

SNY Overall Performance

SNY AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

SNY Recent Performance

-2.39%

Sanofi

0.05%

Avg of Sector

-0.31%

S&P500

SNY PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

SNY Key Information

SNY Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

SNY Profile

Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.

Price of SNY

SNY FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

SNY Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
0.17
PE Ratio (TTM)
20.45
Forward PE
-
PS Ratio (TTM)
2.52
PB Ratio
1.39
Price-to-FCF
18.13
METRIC
VALUE
vs. INDUSTRY
Gross Margin
71.27%
Net Margin
0.80%
Revenue Growth (YoY)
18.14%
Profit Growth (YoY)
16.04%
3-Year Revenue Growth
1.22%
3-Year Profit Growth
3.28%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
0.17
PE Ratio (TTM)
20.45
Forward PE
-
PS Ratio (TTM)
2.52
PB Ratio
1.39
Price-to-FCF
18.13
Gross Margin
71.27%
Net Margin
0.80%
Revenue Growth (YoY)
18.14%
Profit Growth (YoY)
16.04%
3-Year Revenue Growth
1.22%
3-Year Profit Growth
3.28%

  • When is SNY's latest earnings report released?

    The most recent financial report for Sanofi (SNY) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating SNY's short-term business performance and financial health. For the latest updates on SNY's earnings releases, visit this page regularly.

  • Where does SNY fall in the P/E River chart?

    According to historical valuation range analysis, Sanofi (SNY)'s current price-to-earnings (P/E) ratio is 12.17, placing it in the Undervalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • What is the operating profit of SNY?

    According to the latest financial report, Sanofi (SNY) reported an Operating Profit of -1.04B with an Operating Margin of -8.5% this period, representing a decline of 281.15% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is SNY's revenue growth?

    In the latest financial report, Sanofi (SNY) announced revenue of 12.21B, with a Year-Over-Year growth rate of 59.94%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does SNY have?

    As of the end of the reporting period, Sanofi (SNY) had total debt of 20.33B, with a debt ratio of 0.16. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does SNY have?

    At the end of the period, Sanofi (SNY) held Total Cash and Cash Equivalents of 7.66B, accounting for 0.06 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does SNY go with three margins increasing?

    In the latest report, Sanofi (SNY) did not achieve the “three margins increasing” benchmark, with a gross margin of 70.26%%, operating margin of -8.5%%, and net margin of -6.56%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess SNY's profit trajectory and future growth potential.

  • Is SNY's EPS continuing to grow?

    According to the past four quarterly reports, Sanofi (SNY)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -1.48. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What are the PEG ratio and PE ratio of SNY?

    The latest valuation data shows Sanofi (SNY) has a Price-To-Earnings (PE) ratio of 12.17 and a Price/Earnings-To-Growth (PEG) ratio of 0.14. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.